VALENCIA, SPAIN, July 10, 2018 (GLOBE NEWSWIRE) -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held device for the early detection of heart attack at the Point of Care, is pleased to announce that the Company is now trading on the OTC Markets Group OTCQB “Venture Market”.
Investors can find current financial disclosure, company news and Real-Time Level 2 quotes for Zenosense at: http://www.otcmarkets.com/stock/ZENO/quote
The OTCQB is recognized as an Established Public Market by the U.S. Securities and Exchange Commission and is a leading market for entrepreneurial and development stage U.S. and international companies.
To be eligible, companies must be current in their financial reporting, pass a minimum bid price test, and undergo an annual company verification and management certification process. The OTCQB Venture Market quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors. As a verified market with efficient access to U.S. investors, OTCQB helps companies build shareholder value with a goal of enhancing liquidity and achieving fair valuation.
About Zenosense, Inc.
Zenosense Inc., through a joint-venture ownership in MIDS Medical Ltd., is primarily focused on the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac. MIDS Medical applies patent-protected magnetic nanoparticle detection technology and a development team with world-class technical expertise. The MIDS Cardiac device and test strip is being designed to support a variety of rapid high sensitivity cardiac biomarker tests, with a focus on troponin I and T, to identify or discount Acute Myocardial Infarction with accuracy equal or superior to high sensitivity assays performed on laboratory analyzers. To find out more about Zenosense, visit www.Zenosense.com
Forward-Looking Statements
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects,” "intends,” "plans,” "may,” "could,” "should,” "anticipates,” "likely,” "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed on filed on April 17, 2018, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Respective statements concerning the development of both MIDS Cardiac™ and other devices under development have been made based on information obtained from MIDS Medical Ltd. and Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.